Clinical Benefits Of First-Line (1l) Cemiplimab Monotherapy By Pd-L1 Expression Levels In Patients With Advanced Nsclc
JOURNAL OF THORACIC ONCOLOGY(2021)
Key words
non-small cell lung cancer, anti-PD-1, cemiplimab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined